        <DOC>
            	<DOCNO>s_902_0_0</DOCNO>
            	<TEXT>25$ target price... let's goooooo</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_1_0</DOCNO>
            	<TEXT>Waiting for it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_1_1</DOCNO>
            	<TEXT>buy and hold</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_2_0</DOCNO>
            	<TEXT>buy and hold Sorrento Therapeutics (Srne)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_3_0</DOCNO>
            	<TEXT>buy and hold!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_4_0</DOCNO>
            	<TEXT>SRNE - buy and hold</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_4_1</DOCNO>
            	<TEXT>Sorrento Therapeutics (SRNE) will go to the moon</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_5_0</DOCNO>
            	<TEXT>**Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At-Home Outpatient Setting in United Kingdom**</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_6_0</DOCNO>
            	<TEXT>Well done Patience is the key to success!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_7_0</DOCNO>
            	<TEXT>Lees Pharmaceutical Announces First Patient Dosed With its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, as a First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_8_0</DOCNO>
            	<TEXT>BULL: Why I support SRNE?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_8_1</DOCNO>
            	<TEXT>Lets make this post the most commented one.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_8_2</DOCNO>
            	<TEXT>Please share your genuine opinions, feedbacks, ideas about Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_8_3</DOCNO>
            	<TEXT>It can be very helpful for everyone Why do we support SRNE?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_8_4</DOCNO>
            	<TEXT>And remember.. patience is a key element of success.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_9_0</DOCNO>
            	<TEXT>Thanks for sharing this</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_10_0</DOCNO>
            	<TEXT>Thanks!totally agree with you</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_12_0</DOCNO>
            	<TEXT>Good points thanks you said right a lot of stuff going on Rome wasnt build in a day!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_13_0</DOCNO>
            	<TEXT>Hope STIX will get it soon - $300 a share it may sounds too much, but it does not with this kind of pipeline</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_14_0</DOCNO>
            	<TEXT>Glad to hear your feedback</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_15_0</DOCNO>
            	<TEXT>Soon to the moon</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_16_0</DOCNO>
            	<TEXT>Incredible pipeline - who is ready to fly?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_17_0</DOCNO>
            	<TEXT>Thanks for posting!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_18_0</DOCNO>
            	<TEXT>News: Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_19_0</DOCNO>
            	<TEXT>SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, announced today the availability of a presentation on its corporate website to provide an overview of Sorrentos proprietary mRNA vaccine development program for COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_19_1</DOCNO>
            	<TEXT>Highlights of the presentation include: MultiValent COVID Vaccine candidate comprised of proprietary designer Spike-encoding mRNAs designed to elicit cellular and humoral immunity against the early WA-1 virus as well as the predominant variants of concern (VOCs), Alpha, Beta, Gamma, Delta, and Lambda.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_19_2</DOCNO>
            	<TEXT>mRNA construct engineered to remove a furin cleavage site in the native spike protein.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_19_3</DOCNO>
            	<TEXT>This cleavage site could potentially lead to spike protein being cleaved off the cells expressing the protein and then entering the circulation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_19_4</DOCNO>
            	<TEXT>Thermostable mRNA lipid nanoparticle (LNP) formulation that potentially allows for provision of vaccine doses without the need for frozen storage after time of manufacture, during transport and prior to dose administration.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_19_5</DOCNO>
            	<TEXT>Development of equipotent lyophilized dose forms that may further enhance the potential for vaccine delivery to underserved populations due to cold-chain storage and transportation issues.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_19_6</DOCNO>
            	<TEXT>Micro-epidermal infusion patch device potentially elicits a superior immune response thought to be due to the direct lymphatic dose delivery.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_19_7</DOCNO>
            	<TEXT>MultiValent COVID Vaccine administered via Sorrentos proprietary Sofusa MuVa x x TM system achieved equivalent serum IgG responses at one tenth of the dose compared to intramuscular administration in mice based on preclinical studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_19_8</DOCNO>
            	<TEXT>The presentation can be viewed at: https://investors.sorrentotherapeutics.com/events-and-presentations/presentations</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_20_0</DOCNO>
            	<TEXT>News release = Game changing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_20_1</DOCNO>
            	<TEXT>Target price much higher than $28</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_21_0</DOCNO>
            	<TEXT>Check his official account on Twitter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_0</DOCNO>
            	<TEXT>Sorrento and Dyadic Announce Binding Term Sheet to License Dyadics Lead COVID-19 Vaccine Candidate DYAI-100 and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_1</DOCNO>
            	<TEXT>Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadics C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadics lead COVID-19 vaccine candidate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_2</DOCNO>
            	<TEXT>Dyadics lead COVID-19 Vaccine, DYAI-100, utilizes the SARS-CoV-2 Spike Protein receptor binding domain (RBD) and has been extensively studied in vitro and in vivo for its induction of high-titer neutralization activities in vaccinated animals against the SARS-CoV-2 virus and its major variants of concern (VoCs).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_3</DOCNO>
            	<TEXT>MultiValent COVID-19 Vaccine is under development using the RBDs for the VoCs, such as delta, alpha, beta, gamma and lambda, and is designed to cover all known and emerging VoCs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_4</DOCNO>
            	<TEXT>Consideration includes a $10 million upfront payment ($5 million in cash and $5 million in Sorrento stock), reimbursement of certain DYAI-100 R amp;D expenses, with potential for multiple future development milestones and royalty payments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_5</DOCNO>
            	<TEXT>SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, and Dyadic International, Inc. (NASDAQ: DYAI; Dyadic), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, today announced the signing of a binding term sheet to enter into an exclusive license agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadics lead COVID-19 vaccine candidate, DYAI-100, produced using Dyadic's proprietary and patented C1-cell protein production platform.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_6</DOCNO>
            	<TEXT>The final terms of the license will be set forth in a definitive agreement to be entered into between the parties.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_7</DOCNO>
            	<TEXT>Sorrento Chairman and CEO, Dr. Henry Ji, commented, We look forward to continuing our collaboration with Dyadic, which began last year, initially with a goal of developing and commercializing a protein-based COVID-19 vaccine that can be rapidly manufactured in large quantities in our existing cGMP facilities, and stored and transported at room temperature, in order to increase access and affordability to underserved populations globally.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_8</DOCNO>
            	<TEXT>continued, Over the past six months we have carried out several promising preclinical animal studies using the C1-produced RBD antigen in Dyadics lead COVID-19 vaccine candidate, DYAI-100.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_9</DOCNO>
            	<TEXT>Our goal is to manufacture a COVID-19 vaccine that will provide protection across the variants of concern, including Delta, and in addition, apply the C1 protein production platform broadly across our current and future coronavirus programs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_10</DOCNO>
            	<TEXT>Mark Emalfarb, Dyadics President and Chief Executive Officer noted, We are delighted to have executed a binding term sheet with Sorrento Therapeutics to license the C1 technology for the development and commercialization of coronavirus vaccines, therapeutics, and diagnostics, including COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_11</DOCNO>
            	<TEXT>This marks a significant milestone in our corporate development efforts as we expect the license agreement we will enter into to enable us to monetize our internal COVID-19 development efforts with a partner that has the resources and expertise to advance vaccines, therapeutics, and diagnostics both clinically and commercially.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_12</DOCNO>
            	<TEXT>The license agreement, when executed, contemplates an up-front payment of $10 million in cash and stock, up to $4 million in reimbursements for preclinical and clinical development costs incurred by Dyadic for the development and advancement of our proprietary DYAI-100 vaccine, up to $33 million in milestone payments and ongoing royalties following commercialization.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_13</DOCNO>
            	<TEXT>All future development costs related to this license will be incurred by Sorrento, concluded Mr. Emalfarb.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_14</DOCNO>
            	<TEXT>Mr. Michael Tarnok, Dyadics Board Chairman noted, This is a significant event for Dyadic and humankind globally, having achieved our goal of creating a pathway that potentially addresses the COVID-19 vaccine production gap for mass scale immunizations and treatments across the globe, quickly and efficiently.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_22_15</DOCNO>
            	<TEXT>The Sorrento license will cover all other territories not already covered by Dyadics existing COVID-19 agreements with Medytox, Syngene and the Rubic Consortium.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_23_0</DOCNO>
            	<TEXT>Pdf here https://investors.sorrentotherapeutics.com/node/12291/pdf</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_0</DOCNO>
            	<TEXT>NEWS: Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate DYAI-100 Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_1</DOCNO>
            	<TEXT>August 19, 2021 at 4:21 PM EDT[Download PDF](https://investors.sorrentotherapeutics.com/node/12336/pdf) * Immunization with a protein-based immunogen, DYAI-100, a receptor binding domain (RBD) of SARS-CoV-2, resulted in potent B cell immunity in preclinical studies, with strong serological recognition of the original SARS-CoV-2 virus and major variants of concern (Alpha, Beta, Gamma, and Delta; VOCs). *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_2</DOCNO>
            	<TEXT>The sera of vaccinated mice demonstrated potent neutralization of viral infection by the original SARS-COV-2 and major VoCs, such as Beta and Delta, and to a lesser extent Gamma *in vitro* in a live virus challenge Vero-E6 cell model. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_3</DOCNO>
            	<TEXT>Sorrento and its collaboration partner, Dyadic International, Inc., are working together to complete the IND-enabling studies for IND submission for human vaccination trials globally. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_4</DOCNO>
            	<TEXT>A MultiValent RBD-based vaccine utilizing the RBDs from SARS-CoV-2 and its major VoCs is in development to potentially serve as a universal vaccine and potentially as a universal booster for other COVID-19 vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_5</DOCNO>
            	<TEXT>SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, released today a preprint publication, which is accessible at: [https://www.biorxiv.org/content/10.1101/2021.08.17.456704v1.full.pdf](https://www.globenewswire.com/Tracker?data=mkWyRoLl32Au5EsBye09IWFDy1gh5zR_DEEh9Mh_1Yo0flWwqTEwIxjrU-_vnbJ3aSREZpk98_Bzhr0xH5hQvdtuyGKHbi-b4NmnqQlMqHI5BMbWFlxXgnmpb1monRyrMUUA5OU-5a1m9oSQpvUFm8d8h1tqfYHtnd8yYkmhKhdpvNdZUTa8yvXe7KxzfR5rIZfHsOeQ6iIDoYFsYQ3CgA==).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_6</DOCNO>
            	<TEXT>The publication details preclinical vaccination studies of a new to-be-licensed and developed protein-based COVID-19 vaccination candidate, DYAI-100.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_7</DOCNO>
            	<TEXT>The new RBD-based COVID-19 vaccination candidate demonstrated in preclinical studies the potential to elicit potent neutralizing B-cell immune responses against the original SARS-CoV-2 strain and its emerging variants, including Beta and Delta.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_8</DOCNO>
            	<TEXT>The generation of a protein-based vaccination candidate that provides protection against the original SARS-CoV-2 virus and emerging VoCs has proved to be challenging.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_9</DOCNO>
            	<TEXT>The publication reports the protective neutralizing activities of the sera of vaccinated animals against a broad spectrum of SARS-CoV-2 virus and its major VoCs by immunization with recombinant Spike protein receptor binding domain (RBD) administered in conjunction with aluminum-phosphate adjuvant intramuscularly.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_10</DOCNO>
            	<TEXT>Immunizing mice with RBD protein vaccine with simple aluminum-phosphate adjuvant led to the production of IgG antibodies recognizing the Spike protein of the prototype SARS-CoV-2 as well as the VoCs, such as Alpha (United Kingdom), Beta (South Africa), Gamma (Brazil/Japan), and Delta (India).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_11</DOCNO>
            	<TEXT>RBD protein immunization induced to the activation of a Th1 polarization of CD4 positive T cells.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_12</DOCNO>
            	<TEXT>Furthermore, RBD protein immunization produced IgG antibodies *in vivo*, which exerted high neutralizing activity against live SARS-CoV-2 and the highly transmissible VoCs, Beta and Delta, as well as Gamma to a lesser extent.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_13</DOCNO>
            	<TEXT>Thus, DYAI-100 represents a promising COVID-19 vaccination candidate against COVID-19 that may potentially offer broad protective range against emerging VOCs of SARS-CoV-2 virus. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_14</DOCNO>
            	<TEXT>About** **Sorrento Therapeutics, Inc.** Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_15</DOCNO>
            	<TEXT>Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs), and clinical stage oncolytic virus (Seprehvir).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_16</DOCNO>
            	<TEXT>Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD, COVI-AMG, COVISHIELD, Gene-MAb, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK, COVISTIX and COVITRACE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_17</DOCNO>
            	<TEXT>Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (RTX), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_18</DOCNO>
            	<TEXT>RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_19</DOCNO>
            	<TEXT>SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_20</DOCNO>
            	<TEXT>ZTlido was approved by the FDA on February 28, 2018.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_21</DOCNO>
            	<TEXT>For more information visit [www.sorrentotherapeutics.com](https://www.globenewswire.com/Tracker?data=PJg2__PQ8zDaq-3kinor5XLHiDB7P-I5goumNEwdBzamuFj3U1EC7G1ZW5Z6qvYV2eq47ci-K8i6AHPtvFGQFn_UCIMk7NxpvLdcd5qF_Ae90TNSWJLlDXSWiPv8Zzdd). **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_22</DOCNO>
            	<TEXT>Forward-Looking Statements** This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_23</DOCNO>
            	<TEXT>Forward-looking statements include statements regarding DYAI-100 and its properties, including its induction of potent neutralization activity against SARS-CoV-2 and its variants of concern, including Alpha, Beta, Gamma and Delta; the collaboration between Sorrento and Dyadic, including but not limited to, the development of DYAI-100 and completion of IND-enabling studies for DYAI-100; the potential for DYAI-100 to serve as a universal vaccine and as a universal booster for other COVID-19 vaccines; the ability of an RBD protein-based vaccine, including DYAI-100, to elicit strong immunity and produce IgG antibodies against SARS-CoV-2 and its variants of concern when administered intramuscularly in conjunction with an adjuvant, including an aluminum-phosphate adjuvant; and Sorrentos expectation of obtaining licensing rights for DYAI-100 from Dyadic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_24</DOCNO>
            	<TEXT>Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's technologies and prospects, including, but not limited to risks related to seeking regulatory approval for DYAI-100; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist Sorrento in the execution of its therapeutic antibody product candidate strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_25</DOCNO>
            	<TEXT>Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_26</DOCNO>
            	<TEXT>Media and Investor Relations Contact** Alexis Nahama, DVM (SVP Corporate Development) Email: [mediarelations@sorrentotherapeutics.com](https://www.globenewswire.com/Tracker?data=6cMNYKP9T37Rsn2l_n7Bhy5V5TjojknFt6W96IWV4bGPuFOogo4UKDuE4lsxFkEZfZchdR2ppt4GJX-8Mr_FVgmwP6QOLafU_3QE_cndPaVWXsr-ilWCJKqrn28aN4g3zO4H6reqFJI3A1gvOhJIkg==) Sorrento and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc. G-MAB, DAR-T, SOFUSA, COVIGUARD, COVI-AMG, COVISHIELD, Gene-MAb, COVIDROPS, COVI-MSC, COVITRACK, COVITRACE and COVISTIX are trademarks of Sorrento Therapeutics, Inc. SEMDEXA is a trademark of Semnur Pharmaceuticals, Inc. ZTlido is a registered trademark owned by Scilex Pharmaceuticals Inc. All other trademarks are the property of their respective owners.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_24_27</DOCNO>
            	<TEXT>2021 Sorrento Therapeutics, Inc. All Rights Reserved.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_0</DOCNO>
            	<TEXT>NEWS: Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A amp;M University</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_1</DOCNO>
            	<TEXT>MPro is a SARS-CoV-2 enzyme that catalyzes the formation of a number of essential proteins for the viral reproduction.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_2</DOCNO>
            	<TEXT>MPro inhibitors block this catalytic process to potentially inhibit the viral replication in human cell hosts and prevent viral infection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_3</DOCNO>
            	<TEXT>The lead compound, MPI8, exhibited potent in vitro antiviral activity against SARS-CoV-2 and all of the major Variants of Concern (VoCs) (alpha, beta, delta and gamma) tested.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_4</DOCNO>
            	<TEXT>Sorrento intends to develop the lead MPro inhibitor in oral administration form and as a component of an antiviral cocktail therapy to potentially eliminate current and emerging coronavirus infections.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_5</DOCNO>
            	<TEXT>SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has entered into an option agreement (Option) with The Texas A amp;M University System (TAMUS) for exclusive rights to the intellectual property covering highly potent main protease (MPro) inhibitors against SARS-CoV-2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_6</DOCNO>
            	<TEXT>This latest agreement bolsters Sorrentos wide-ranging portfolio of preclinical and clinical therapeutic candidates targeting COVID-19, including new and emerging variants of concern of the SARS-CoV-2 virus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_7</DOCNO>
            	<TEXT>Under the terms of the agreement, Sorrento has an exclusive option to exclusively license patents covering the MPro inhibitor drug candidates.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_8</DOCNO>
            	<TEXT>Discovered and developed by Dr. Wenshe Ray Liu and his research team at Texas A amp;M University, the MPro inhibitors have demonstrated strong cellular antiviral potency against SARS-CoV-2 in preclinical studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_9</DOCNO>
            	<TEXT>Several MPro inhibitors were identified that exhibited antiviral effects against diverse SARS-CoV-2 variants, including Indian (Delta), UK (Alpha), Brazilian (Beta) and South Africa (Gamma) variants of concern.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_10</DOCNO>
            	<TEXT>The potential advantage of using small molecules, in oral and/or intravenous administration, that target MPro is that they are not affected by mutations in the SARS-CoV-2 spike protein, which may enable MPro drugs to be effective against SARS-CoV-2 and its variants of concern (VOCs), as well as against other coronaviruses that currently exist or might emerge in the future.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_11</DOCNO>
            	<TEXT>MPro is a SARS-CoV-2 enzyme that catalyzes the formation of a number of essential proteins for the viral reproduction.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_12</DOCNO>
            	<TEXT>MPro inhibitors block this catalytic process to inhibit the viral replication in human cell hosts achieving the eradication of the virus, according to Dr. Liu.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_13</DOCNO>
            	<TEXT>We are excited to be collaborating with Dr. Liu and his team at Texas A amp;M and look forward to advancing the development of these novel drug candidates to address COVID-19, and a multitude of other respiratory viruses, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_14</DOCNO>
            	<TEXT>This agreement further strengthens our dynamic COVID-19 product portfolio and is well aligned with our overall strategic plan to combat COVID-19 through a combination of potent small molecules and antibodies, cellular therapies and vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_25_15</DOCNO>
            	<TEXT>Sorrento may exercise its right to enter into a worldwide exclusive license agreement at any time during the option period.[link](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-announces-entry-option-agreement)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_26_0</DOCNO>
            	<TEXT>Waiting for any approval.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_26_1</DOCNO>
            	<TEXT>Expectation for Sorrento are too high.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_0</DOCNO>
            	<TEXT>NEWS: Sorrento Exercises Exclusive Option Agreement With Texas A amp;M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_1</DOCNO>
            	<TEXT>* Exclusive license for MPro inhibitors supports rapidly growing small molecule development portfolio for combating COVID-19. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_2</DOCNO>
            	<TEXT>Lead compound, MPI8, exhibited potent *in vitro* antiviral activity against SARS-CoV-2 and all of the major Variants of Concern (VoCs) (alpha, beta, delta and gamma). *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_3</DOCNO>
            	<TEXT>MPI8 also demonstrated superior antiviral activity in a head-to-head comparison with a late-stage clinical antiviral compound (EIDD-2801). *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_4</DOCNO>
            	<TEXT>Based on the IC50 data of the Plague Reduction Neutralization Test (PRNT) of live virus infecting Vero E6 cells, MPI8 demonstrated approximately ten-fold (10x) higher antiviral potency than EIDD-2801 against SARS-CoV-2 and its Alpha (UK) and Delta (Indian) VoCs and three to seven-fold (3-7x) higher antiviral potency against Beta (South Africa, 3X) and Gamma (Brazil/Japan, 6-7X) VoCs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_5</DOCNO>
            	<TEXT>SAN DIEGO, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has notified The Texas A amp;M University System (TAMUS) of its exercise of the option to an exclusive license for the global development and commercialization of highly potent main protease (MPro) inhibitors against SARS-CoV-2 and all current and emerging variants of concern (VOCs).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_6</DOCNO>
            	<TEXT>Sorrento and TAMUS previously announced the signing of the option agreement on August 24th and 25th, respectively: * [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-announces-entry-option-agreement](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-announces-entry-option-agreement) * [https://today.tamu.edu/2021/08/25/texas-am-researcher-new-drug-could-be-game-changer-against-covid-19](https://today.tamu.edu/2021/08/25/texas-am-researcher-new-drug-could-be-game-changer-against-covid-19) Sorrentos decision to immediately exercise its option is based on very promising preclinical data for the lead compound, MPI8, that shows highly potent broad-spectrum antiviral activity against SARS-CoV-2 and all of the major Variants of Concern (VoCs) (alpha, beta, delta and gamma).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_7</DOCNO>
            	<TEXT>Based on initial *in vitro* data, MPI8 demonstrated superior antiviral activity in a head-to-head comparison with a current Phase 3 investigational oral antiviral agent (EIDD2801).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_8</DOCNO>
            	<TEXT>Based on the IC50 data of the Plague Reduction Neutralization Test (PRNT) of live virus infecting Vero E6 cells, MPI8 demonstrated approximately ten-fold (10x) higher antiviral potency than EIDD-2801 against SARS-CoV-2 and its Alpha (UK) and Delta (Indian) VoCs and three to seven-fold (3-7x) higher antiviral potency against Beta (South Africa, 3X) and Gamma (Brazil/Japan, 6-7X) VoCs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_9</DOCNO>
            	<TEXT>Sorrento expects to complete additional preclinical studies in the coming weeks, including a head-to-head comparison against other late-stage clinical candidates, and will publish its preliminary findings in a pre-print publication. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_10</DOCNO>
            	<TEXT>About** **Sorrento Therapeutics, Inc.** Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_11</DOCNO>
            	<TEXT>Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_12</DOCNO>
            	<TEXT>Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVIGUARD, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK, COVISTIX and COVITRACE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_13</DOCNO>
            	<TEXT>Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (RTX), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_14</DOCNO>
            	<TEXT>RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_15</DOCNO>
            	<TEXT>SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_27_16</DOCNO>
            	<TEXT>ZTlido was approved by the FDA on February 28, 2018.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_0</DOCNO>
            	<TEXT>NEWS: Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_1</DOCNO>
            	<TEXT>September 2, 2021 at 11:34 AM EDT [Download PDF](https://investors.sorrentotherapeutics.com/node/12396/pdf) * First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_2</DOCNO>
            	<TEXT>Second site scheduled to start enrolling within one week, with multiple additional sites coming online within one month.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_3</DOCNO>
            	<TEXT>SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announcedtodaythe start of enrollment in itsPhase 2efficacy study ofhumanallogeneicadipose-derivedmesenchymal stemcells(COVI-MSC)forpatients suffering from COVID-19-induced acute respiratory distress (ARD)oracute respiratory distress syndrome (ARDS) in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_4</DOCNO>
            	<TEXT>Thisstudy (MSC-COV-202BR) is a multi-arm, randomized, placebo-controlled Phase 2 study of the efficacy and safety ofthree infusions of COVI-MSCadministered on varying schedules in the setting of standard of care treatments for COVID-19 in 100 subjects.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_5</DOCNO>
            	<TEXT>The primaryobjectiveof this study is to evaluate the efficacy of COVI-MSCsin patients with COVID-19-induced ARDor ARDS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_6</DOCNO>
            	<TEXT>Additionally, Sorrento will soon begin enrollment for two additional Phase 2 studies with COVI-MSC: 1.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_7</DOCNO>
            	<TEXT>A parallel Phase 2 placebo-controlled Phase 2 safety study to be conducted across multiple sites inthe United States.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_8</DOCNO>
            	<TEXT>A pulmonary long-hauler Phase 2 safety and efficacy study across multiple sites in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_9</DOCNO>
            	<TEXT>Dr.Henry Ji, Chairman and CEO ofSorrento Therapeutics, stated, It brings us great pleasure to see our MSC treatments for COVID-19-induced ARD/ARDS and post-COVID pulmonary long-haul syndrome rapidly move forward in clinical trials and towards a potential emergency approval of this promising therapy globally.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_10</DOCNO>
            	<TEXT>We believe that COVI-MSC can help save lives, which is our primary goal at Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_11</DOCNO>
            	<TEXT>More information on the three Phase 2 trials can be found at[www.clinicaltrials.gov](https://www.globenewswire.com/Tracker?data=GyaXRCi8TdTyhNR1ycgYw-xZJtbs_Nfl30eN_Ux4pe_o2Ypd65D_-PukEUPL_pQvPYjhoYyf_i9LoE5haSiGDgIqRWYfjKv38jxrb3N1lMc=)(NCT04903327, NCT04905836 and NCT04992247).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_12</DOCNO>
            	<TEXT>Mesenchymal stem cells have been demonstrated to support resolution of symptoms in multiple disease settings and have the potential to reduce the long-term effects associated with pulmonary tissue damage.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_13</DOCNO>
            	<TEXT>More information on the potential use and benefits of MSCs for patients with COVID-19 can be found in the recently published review at:[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02380-2](https://www.globenewswire.com/Tracker?data=es_yN7-NPWejcNqVSFqLAsJRY3P0BlRUGKIowq0xeXxlZIZyarboq4pwcsZ16erhh0efQyHBl-d-DpcCscyOISIU2sI0hjMjUCCKzoZdnkOR2IPo8APBZKdIKGICL5Ou3MqiPa3UEzEyz7hFyJ12OD4W-Fqu7DNkNi1MT9UIl7IhszW1w-T-6d5fZLXcyH3pMmm2JUyScfH8-qSa1qVIl6vx-toDqlZei0gFUzLX6E2yTjbgmR_kooY5xiamUkey). *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_14</DOCNO>
            	<TEXT>Personalized Stem Cells, Inc.(PSC)is Sorrentos GMP manufacturingpartner for COVI-MSC.* **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_15</DOCNO>
            	<TEXT>About** **Sorrento Therapeutics, Inc.** Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_16</DOCNO>
            	<TEXT>Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_17</DOCNO>
            	<TEXT>Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVIGUARD, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK, COVISTIX and COVITRACE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_18</DOCNO>
            	<TEXT>Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (RTX), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_19</DOCNO>
            	<TEXT>RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_20</DOCNO>
            	<TEXT>SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_21</DOCNO>
            	<TEXT>ZTlido was approved by the FDA on February 28, 2018.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_29_22</DOCNO>
            	<TEXT>For more information visit [www.sorrentotherapeutics.com](https://www.globenewswire.com/Tracker?data=wNFZkyl5_rl-catSlfb1gq_wbPPJkNtTUscRW2LLBIfj2s9HBKd8mWJ7neZ2yEtPqltvwzyVsWwjELRtrt9PUBX2rfCgi1q1clzLHqE4M6d2OVcVGnF2x3DAFsNgFnOE).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_30_0</DOCNO>
            	<TEXT>News Release: Sorrentos License Partner, Lees Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_31_0</DOCNO>
            	<TEXT>NEWS: Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_31_1</DOCNO>
            	<TEXT>December 9, 2021 at 9:00 AM EST [Download PDF](https://investors.sorrentotherapeutics.com/node/12896/pdf) * Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announces highly significant positive top-line results from its Phase 3 SP-102 (SEMDEXA) Pivotal Trial C.L.E.A.R Program for its novel, non-opioid, corticosteroid formulation, injectable dexamethasone sodium phosphate viscous gel product for the treatment of lumbosacral radicular pain (sciatica).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_31_2</DOCNO>
            	<TEXT>SP-102 (SEMDEXA) has received Fast Track status from the FDA. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_31_3</DOCNO>
            	<TEXT>The C.L.E.A.R. Program trial has met the primary efficacy and key secondary efficacy endpoints with highly statistical significance: * For the primary endpoint of change in average daily pain (as measured by the Numeric Pain Rating Scale) in the affected leg over 4 weeks following the initial injection the LS Mean (SE) group difference of -1.08 (0.17) compared to placebo with a p-value 
    0.001.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_31_4</DOCNO>
            	<TEXT>two="" key="" secondary="" endpoints="" assessing="" Oswestry="" Disability="" Index="" and="" Time="" open-label="" repeat="" injection="" have="" also="" demonstrated="" highly="" statistically="" significant="" results="" for="" SP-102.="" The="" LS="" Mean="" group="" difference="" in="" ODI="" compared="" to="" placebo="" at="" week="" was="" with="" a="" p-value=""
      0.001.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_31_5</DOCNO>
            	<TEXT>A="" Cox="" proportional="" hazard="" model="" showed="" significantly="" longer="" duration="" of="" initial="" SP-102="" treatment="" compared="" to="" placebo="" Hazard="" Ratio="" with="" a="" p-value=""
        0.001.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_31_6</DOCNO>
            	<TEXT>expects="" be="" first="" FDA-approved="" non-opioid="" potential="" replace="" current="" off-label="" administered="" each="" year="" where="" more="" than="" million="" people="" suffer="" This="" expected="" grow="" as="" overall="" population="" ages.="" PALO="" Dec.="" Scilex="" Holding="" Company="" subsidiary="" Sorrento="" Inc.="" today="" announced="" highly="" significant="" positive="" top-line="" results="" its="" Phase="" Pivotal="" corticosteroid="" injectable="" dexamethasone="" sodium="" phosphate="" viscous="" gel="" treatment="" or="" sciatica.="" has="" received="" Fast="" Track="" status="" from="" FDA.="" C.L.E.A.R.="" Trial="" Lumbosacral="" Epidural="" Analgesia="" for="" was="" designed="" investigate="" safety="" analgesic="" effects="" single="" and="" repeat="" transforaminal="" injections="" SP-102="" enrolled="" low="" back="" subjects="" unilateral="" intervertebral="" disc="" herniation="" lumbosacral="" spine="" resulting="" radicular="" symptoms="" moderate="" severe="" pain.="" It="" is="" largest="" known="" randomized="" well-controlled="" trial="" sciatica="" using="" epidural="" steroid="" injections.="" The="" primary="" endpoint="" change="" average="" daily="" pain="" in="" affected="" leg="" over="" weeks="" following="" the="" initial="" injection="" had="" demonstrated="" LS="" Mean="" group="" difference="" of="" compared="" to="" placebo="" with="" a="" p-value=""
          0.001.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_31_7</DOCNO>
            	<TEXT>two="" key="" secondary="" endpoints="" assessing="" Oswestry="" Disability="" Index="" and="" Time="" open-label="" repeat="" injection="" had="" also="" demonstrated="" highly="" statistically="" significant="" results.="" The="" LS="" Mean="" group="" difference="" in="" ODI="" compared="" to="" placebo="" at="" week="" was="" with="" a="" p-value=""
            0.001.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_31_8</DOCNO>
            	<TEXT>Following="" the="" observation="" moderate="" severe="" radicular="" pain="" could="" receive="" an="" open-label="" injection="" Between="" weeks="" repeat="" injections="" were="" administered="" and="" subjects="" who="" initially="" received="" active="" treatment.="" A="" Cox="" proportional="" hazard="" model="" showed="" significantly="" longer="" duration="" of="" initial="" SP-102="" treatment="" compared="" to="" placebo="" Hazard="" Ratio="" with="" a="" p-value=""
              0.001.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_902_31_9</DOCNO>
            	<TEXT>clean="" profile="" identified="" risks.="" adverse="" events="" special="" interest="" reported="" injections.="" SAEs="" procedure.="" receive="" evaluate="" characterize="" top-line="" remarkable.="" They="" greatly="" community="" enable="" us="" proceed="" plans="" registering="" subacute="" plan="" C.L.E.A.R="" upcoming="" scientific="" conferences="" submit="" publication="" peer="" reviewed="" Dmitri="" intends="" been="" pre-clinical="" designed="" expects="" present="" robust="" collected="" course="" companys="" multi-year="" program="" Application="" contains="" injection.="" it="" show="" More="" fact="" potentially="" life-threatening="" occurred="" States14="" almost="" were="" opioid-related.="" Over="" involved="" opioid.15="" Provisional="" showed="" drug="" overdose="" deaths="" rose="" period="" ending="" April="" anxiously="" awaiting="" submission="" based="" multi-center="" trial.="" indication="" administration="" extended="" relief.="" welcome="" addition="" armamentarium="" interventional="" providing="" alternative="" condition="" affecting="" Dr.="" Critical="" Care="" Psychiatry="" Behavioral="" Sciences="" Johns="" Hopkins="" School="" Professor="" Anesthesiology="" Physical="" Rehabilitation="" Walter="" Reed="" Military="" Medical="" Uniformed="" Services="" University="" Sciences.="We" pleased="" have="" achieved="" milestone="" like="" commend="" experienced="" investigators="" advisors="" C.L.E.A.R.="" persistence="" diligence="" enrolling="" through="" enabling="" landmark="" milestone.="" These="" positive="" encouraging="" news="" many="" millions="" worldwide="" who="" confronting="" look="" forward="" sharing="" complete="" next="" We="" believe="" suffering="" very="" painful="" said="" President="" Chief="" Executive="" Officer="" Scilex.="" By="" number="" across="" Medicare="" private="" coverage="" procedures="" comprising="" approximately="" all="" ESIs="" study="" Consulting.="" Despite="" widespread="" utilization="" persist="" particulate="" solution="" steroids="" effect="" off-label="" use.="" Opioid="" prescriptions="" account="" carry="" well-known="" abuse="" underscoring="" alternate="" societal="" significant="" medical="" exists="" within="" non-particulate="" ESI="" demonstrates="" controlled="" evaluations.7="" than="" grow="" overall="" population="" Many="" experience="" intolerance="" inadequate="" response="" current="" nonsteroidal="" anti-inflammatory="" drugs="" There="" great="" need="" highly="" effective="" analgesic="" medications="" provide="" patient="" without="" toxicity="" tolerability="" challenges="" NSAIDs="" opioids.2="" affects="" Americans="" costs="" much="" billion="" each="" according="" recent="" Institute="" Medicine="" called="" how="" managed6="" nearly="" million="" suffer="" lower="" U.S.8="" Government="" payers="" looking="" alternatives="" opioids="" reduce="" risk="" dependency="" serious="" side="" respiratory="" depression="" while="" still="" offering="" potent="" solutions="" people="" living="" ZTLIDO="" shows="" sales="" growth="" over="" year="" despite="" continued="" impact="" pandemic.="" novel="" lumbar="" particulates.="" pre-filled="" syringe="" administered="" Based="" preclinical="" studies="" extends="" residency="" time="" site="" safety="" concerns="" led="" warn="" using="" injectable="" steroid="" formulations="" route="" administration.="" stage="" biopharmaceutical="" new="" autoimmune="" disease="" COVID-19.="" multipronged="" approach="" fighting="" possible="" extensive="" immuno-oncology="" key="" assets="" fully="" human="" antibodies="" immuno-cellular="" antibody-drug="" conjugates="" oncolytic="" virus="" antiviral="" vaccines="" COVI-MSC="" diagnostic="" test="" COVISTIX.="" commitment="" life-enhancing="" demonstrated="" effort="" advance="" first-in-class="" small="" resiniferatoxin="" commercialize="" post-herpetic="" neuralgia.="" RTX="" has="" completed="" intractable="" cancer="" osteoarthritis="" patients.="" sciatica.="" was="" February="" dedicated="" acute="" uncompromising="" focus="" global="" management="" leader="" committed="" ethical="" principles="" responsibly="" develop="" pharmaceutical="" products="" maximize="" quality="" life.="" targets="" indications="" high="" unmet="" needs="" large="" market="" therapies="" patients="" moderate="" severe="" launched="" October="" developing="" late-stage="" includes="" candidate="" candidate.="" Its="" commercial="" prescription="" lidocaine="" Food="" Administration="" relief="" pain="" associated="" postherpetic="" post-shingles="" nerve="" three="" dexamethasone="" sodium="" phosphate="" containing="" viscous="" gel="" widely="" used="" corticosteroid="" injections="" treat="" lumbosacral="" radicular="" Fast="" Track="" SP-103="" topical="" triple-strength="" formulation="" mg="" Delayed="" Burst="" Release="" Dose="" Naltrexone="" Hydrochloride="" treatment="" fibromyalgia="" multiple="multiple" programs="" initiated="" year.="" efficacy="" see="" NCT="" identifier="" NCT03372161="" Lumbar="" Epidural="" Analgesia="" Radiculopathy="" Full="" Text="" View="" On="" December="" announced="" entering="" letter="" headquartered="" operations="" both="" Palo="" Alto="" San="" California.="" further="" please="" visit="" blank="" check="" formed="" purpose="" effecting="" asset="" share="" reorganization="" similar="" one="" more="" businesses="" entities.="" Where="" Find="" references="" SPAC.="" does="" exchange="" In="" described="" contingent="" execution="" merger="" agreement="" security="" holders="" urged="" read="" amendments="" supplements="" files="" because="" important="" preliminary="" definitive="" relevant="" materials="" they="" become="" documents="" filed="" SEC="" obtained="" free="" charge="" upon="" written="" request="" to:="" Vickers="" Vantage="" Corp.="" I="" Broad="" Floor="" NY="" If="" execute="" description="" available="" at="" SECs="" website="" Additional="" contained="" when="" available.="" also="" deemed="" participants="" proxies="" shareholders="" connection="" combination.="" Information="" about="" directors="" executive="" officers="" information="" interests="" included="" transaction.="" consent="" authorization="" respect="" constitute="" sell="" an="" buy="" combined="" company="" nor="" there="" jurisdiction="" solicitation="" sale="" unlawful="" qualification="" laws="" state="" jurisdiction.="" No="" offer="" shall="" means="" prospectus="" requirements="" amended.="" This="" made="" during="" presentation="" meeting="" concerning="" matters="" discussed="" contain="" under="" safe="" harbor="" provisions="" Section="" Private="" Litigation="" Reform="" Act="" subject="" projected.="" Forward-looking="" common="" Nasdaq="" stock="" ticker="" symbol="" such="" will="" file="" registration="" Form="" S-4="" include="" proxy="" estimated="" anticipated="" likelihood="" successfully="" opportunities="" cash="" resources="" uses="" expectation="" would="" first="" FDA-approved="" non-opioid="" epidural="" injection="" intent="" use="" pivotal="" Phase="" trial="" discuss="" licensure="" application="" Breakthrough="" Designation="" Status="" sciatica="" support="" New="" well="" NDA="" filing="" statements="" regarding="" if="" approved="" development="" commercialization="" prospects="" technologies="" potential="" product="" candidates="" best-in-class="" therapies.="" Risks="" uncertainties="" could="" cause="" Scilexs="" actual="" differ="" materially="" adversely="" those="" expressed="" our="" but="" limited="" Scilexand="" being="" able="" enter="" into="" Merger="" Agreement="" inability="" consummate="" combination="" failure="" meet="" applicable="" changes="" timing="" completion="" transaction="" between="" SPAC="" continue="" listing="" Capital="" Market="" until="" Companys="" list="" its="" securities="" NASDAQ="" after="" closing="" achieve="" benefits="" including="" future="" financial="" operating="" Combined="" ability="" realize="" expected="" synergies="" outcome="" legal="" proceedings="" instituted="" against="" parties="" following="" announcement="" proposed="" general="" political="" business="" related="" ongoing="" COVID-19="" pandemic="" that="" prior="" clinical="" trials="" regulatory="" intellectual="" set="" forth="" Sorrentos="" SPACs="" filings="" with="" Securities="" Exchange="" Commission.="" Investors="" cautioned="" not="" place="" undue="" reliance="" these="" which="" speak="" only="" date="" we="" undertake="" no="" obligation="" update="" any="" forward-looking="" statement="" this="" press="" release="" except="" as="" may="" be="" required="" law.="" Investor="" Contact:="" Jaisim="" CEO="" Company="" Email:="" Website:="" logo="" ZTlido="" G-MAB="" respectively.="" SEMDEXA="" Semnur="" Pharmaceuticals="" Scilex="" Holding="" Company.="" A="" proprietary="" name="" FDA="" planned.="" COVITRACK="" COVISTIX="" Seprehvir="" is="" registered="" trademark="" VirttuBiologics="" wholly="" subsidiary="" TNK="" part="" group="" companies="" owned="" trademarks="" are="" the="" property="" their="" respective="" owners.="" All="" Rights="" Reserved.="" Decisions="" Resources="" Group.="" Pain:="" Landscape="" Forecast.="" IOM:="" Million="" Plus="" in="" Emily="" P.="" Washington="" MedPage="" Today="" June="" Proprietary="" Syneos="" SP-102="" Sciatica="" Internal="" March="" Crow="" Willis="" Decision="" Resources:="" Chronic="" Report="" Abdel="" Shaheed="" Maher="" Williams="" Day="" McLachlan="" AJ.="" dose-dependent="" effects="" analgesics="" low="" back="" meta-analysis.="" JAMA="" Hudson="" Edlund="" Steffick="" Tripathi="" MD.="" Epidemiology="" regular="" prescribed="" use:="" results="" from="" population-based="" survey.="" J="" Pain="" Symptom="" Manage="" Chaparro="" Furlan="" Deshpande="" Mailis="" Gagnon="" Atlas="" Turk="" DC.="" Opioids="" compared="" placebo="" or="" other="" treatments="" low-back="" pain.="" Cochrane="" Database="" Syst="" Rev="" CD004959="" Chou="" Turner="" Devine="" Hansen="" Sullivan="" Blazina="" et="" al.="" The="" effectiveness="" long-term="" opioid="" therapy="" chronic="" pain:="" systematic="" review="" a="" National="" Institutes="" Health="" Pathways="" to="" Workshop.="" Ann="" Intern="" Med="" Annual="" surveillance="" report="" of="" drug-related="" risks="" outcomes="" United="" Centers="" Disease="" Control="" and="" Prevention="" U.S.="" News="" by="" Steven="" Ross="" Johnson:="" CDC="" Data="" on="" Drug="" Overdose="" Deaths="" Top="" for="" First="" November="" Source:="" Sorrento="" Inc.=""
                </TEXT>
        </DOC>
